Alzinova Ab · OMXSTO:ALZ
Alzinova Ab — Investor Presentation (September 2021)
17 slides from Alzinova Ab's investor presentation, Sep 1, 2021
Slide 1: Alzinova – Company Presentation
Alzinova – Company Presentation
Slide 2: Forward Looking Statements
Forward Looking Statements This information contains forward-looking statements that reflect the Company's intentions, beliefs, or current expectations about and targets for the Company's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strate
Slide 3: Alzinova – developing first oligomer-specific vaccine against Alzheimer's disease
Alzinova – developing first oligomer-specific vaccine against Alzheimer’s disease Swedish biopharma company Based in Gothenburg. Founded: 2011 High unmet medical need for Alzheimer’s disease Innovative science and proprietary technology enables development of disease-modifying treatments for Alzheim
Slide 4: Alzheimer's disease, a progressively debilitating disease with the highest unmet medical need
Alzheimer’s disease, a progressively debilitating disease with the highest unmet medical need • 50 million patients have dementia (>150 million in 2050) • Alzheimer’s = 60-80% of all dementia • Impacts quality of life for patients and their families • Annual cost of dementia: US $1 trillion (2018),
Slide 5: Alzinova – product pipeline targeting Alzheimer's Disease
Alzinova – product pipeline targeting Alzheimer’s Disease Candidates Discovery Pre-clinical Clinical NDA/MAA Next Planned Milestone ALZ-1011) therapeutic Q3 2021 Start clinical vaccine phase 1b ALZ-2012) monoclonal antibody 1) Phase 1b study in patients with Alzheimer’s 2) Humanization of monoclonal
Slide 6: Alzinova's products are based on proprietary AβCC peptide technology
Alzinova’s products are based on proprietary AβCC peptide™ technology This enables the development of disease-modifying therapies that target, with high precision, the toxic amyloid-β oligomers that damage brain synapses in the onset and progression of the disease. ALZ-101 - antigen ALZ-101, a uniqu
Slide 7: New generation anti-amyloid-β immunotherapy
New generation anti-amyloid-β immunotherapy Non-specific binding Non-specific binding Specific binding Aggregated Aβ Oligomer-specific targeting Aβ40 Aβ42 Toxic forms (oligomers) Insoluble Aβ forms (fibrils) Side effects (ARIA:s) Side effects (ARIA:s) Best in-class potential No clinical benefit Sign
Slide 8: ALZ-101 represents a breakthrough in Alzheimer's Disease
ALZ-101 represents a breakthrough in Alzheimer's Disease • Highly specific therapeutic vaccine, directed towards the neurotoxic oligomeric Aβ • Opportunity to become an effective and well tolerated treatment to halt and reverse Alzheimer’s • Best-in-class potential Immunotherapeutic drug candidates,
Slide 9: Alzinova is developing two oligomer-specific products
Alzinova is developing two oligomer-specific products • Alzinova has two oligomer-specific products: − ALZ-101 vaccine − ALZ-201 monoclonal antibody • Vaccines as treatment modality offer advantages: − High patient compliance (few booster doses) − Cost effective − Preventive treatment possible 9 ©20
Slide 10: ALZ-101 data and documentation supports initiation of a clinical study in Q3 2021
ALZ-101 data and documentation supports initiation of a clinical study in Q3 2021 Transgenic mice vaccinated with ALZ-101 • Comprehensive package supporting clinical phase 1b study showed a 25% increase of synapse density – ALZ-101 is well tolerated in non-clinical toxicity studies ✓ compared to con
Slide 11: ALZ-101 First in Human Study, Phase 1b in patients with Alzheimer's disease
ALZ-101 First in Human Study, Phase 1b in patients with Alzheimer’s disease Site Clinical Research Service Turku (CRST) Finland Subjects 26 patients - mild AD or MCI due to AD Study design Randomized, placebo controlled, double-blind Treatment Two doses ALZ-101 and placebo Study duration 20 weeks tr
Slide 12: Alzinova - Business Model
Alzinova - Business Model • Develop novel disease-modifying immunotherapies based on proprietary AβCC technology • Document safety and tolerability in patients with Alzheimer’s disease • In parallel, prepare for phase 2, to optimize the value of the candidates • “Phase 2-ready” candidates – partner
Slide 13: Experienced management team and innovation-focused collaborations
Experienced management team and innovation-focused collaborations Kristina Torfgård, PhD Anders Sandberg, PhD Anders Bylock, MD, PhD Chief Executive Officer Chief Scientific Officer and Chief Medical Officer Co-Founder >25 years experience – >30 years experience – AstraZeneca, Albireo >20 years expe
Slide 14: Board of Directors with extensive pharma and biopharma experience
Board of Directors with extensive pharma and biopharma experience Björn Larsson Anders Blom Per-Göran Gillberg, PhD Chair of the Board >25 years experience – 35 years in experience – >25 years experience – Pharmacia & Upjohn, Q-Med AB, Kabi, Kabi Pharmacia, Pharmacia & Novo Nordisk, AstraZeneca, Nex
Slide 15: Summary: ALZ-101 represents a potential breakthrough for the treatment of Alzheimer's patients
Summary: ALZ-101 represents a potential breakthrough for the treatment of Alzheimer’s patients • High unmet medical need for disease-modifying treatments of Alzheimer’s disease • Short-term goal is to initiate the first oligomer-specific clinical trial with a therapeutic vaccine in patients by Q3 20
Slide 16: Capitalisation table, summary of shares and options
Capitalisation table, summary of shares and options Shareholders, as per 30 June 2021: Capitalization table (amounts in million SEK): Market cap, as per 30 Aug. 2021 126.2 Subscription warrants TO 2020/2022 (SEK 8,75 WAEP) 2.) 35.6 Share options incentive program 2020/2023 (SEK 22,50 WAEP) 3.3 Total
Slide 17: Thank you!
alzinova® Thank you!